fig1

Statins markedly potentiate aminopeptidase inhibitor activity against (drug-resistant) human acute myeloid leukemia cells

Figure 1. Growth inhibitory effects of CHR2863 for (A) U937/WT, (B) U937/CHR2863R0.2 and (C) U937/CHR2863R5 cells in the absence and presence of maximal non-toxic concentrations of simvastatin (2 µM, 2.5 µM, and 2.5 µM, respectively). Cell growth inhibition was determined after 72 h of drug exposure. The results depicted are the mean ± SE of 6-10 separate experiments; (D) Combination index - fraction affected plot from (A-C) of the combination simvastatin (fixed concentration) and CHR2863 for U937/WT, U937/CHR2863R0.2 and U937/CHR2863R5 cells. CHR2863: (6S)-[(R)-2-((S)-Hydroxy-hydroxycarbamoyl-methoxy-methyl)-4-methyl-pentanoylamino]-3,3 dimethyl-butyric acid cyclopentyl ester.

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/